Uterine cancer

Immatics Announces First Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, May 16, 2023
Synovial sarcoma, Paul Ehrlich Institute, Prevalence, Half-life, CRS, Clinical trial, Lung cancer, CTA, Uveal melanoma, Head, Bristol Myers Squibb, Research, Cohort study, PRAME, TCR, CTA4, Development, State Administrative Expenses, Cytokine release syndrome, Patient, PEI, Administration, Entrepreneurship, Toxic epidermal necrolysis, Uterine cancer, Ovarian cancer, Resuscitation, Safety, Breast cancer, Pharmaceutical industry, Cryptocurrency, Vaccine, Medical imaging

Objective responses were observed independent of solid tumor type at low, medium and high PRAME expression levels above Immatics’ MS-guided RNA threshold.

Key Points: 
  • Objective responses were observed independent of solid tumor type at low, medium and high PRAME expression levels above Immatics’ MS-guided RNA threshold.
  • Next update on Immatics’ IMA203 Phase 1b cohorts, including the projected clinical development path for PRAME TCR-T monotherapy towards registration-directed trials and potential commercialization is planned for 4Q 2023.
  • The trial is expected to commence in 2H 2023 with a first clinical data interim report planned in 2024.
  • Nancy Valente, M.D., resigned from her position on Immatics’ Board of Directors effective May 12, 2023.

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

Retrieved on: 
Tuesday, May 2, 2023
Synovial sarcoma, Paul Ehrlich Institute, PD, Prevalence, DSMB, Half-life, CRS, DL, RECIST, DLT, Cancer, Lung cancer, BOR, Uveal melanoma, Head, Cohort study, RNA, EDT, PRAME, TCR, ORR, CTA4, Data monitoring committee, Cytokine release syndrome, MD, PEI, Patient, Data, Blood, CEST, Webcast, Ovarian cancer, Uterine cancer, Resuscitation, SD, PR, Safety, Breast cancer, Nivolumab, Pharmaceutical industry, Platinum, Fine chemical, Vaccine, Medical imaging

These data further increase our confidence in the success and broad potential of targeting PRAME, and our product candidate IMA203.

Key Points: 
  • These data further increase our confidence in the success and broad potential of targeting PRAME, and our product candidate IMA203.
  • No dose-dependent increase of CRS was observed across Phase 1a and Phase 1b Cohort A (N=38 patients infused with IMA203 in total).
  • Clinical activity for IMA203 TCR-T monotherapy in Phase 1b Cohort A: IMA203 monotherapy demonstrates a high rate of deep objective responses with ongoing durability of more than 9 months after treatment in some patients.
  • Immatics will host a conference call today, May 2nd, 2023, at 8:30 am EDT / 2:30 pm CEST to discuss the clinical data.

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors

Retrieved on: 
Wednesday, March 8, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ADC, Ovarian cancer, Colorectal cancer, Prostate cancer, Cancer, TACSTD, Thyroid cancer, Cell membrane, Neoplasm, Bystander effect, Esophageal cancer, Cervical cancer, DAR, TACSTD2, Glioma, Uterine cancer, Pancreatic cancer, Tissue, Drug discovery, Patient, Lung cancer, Index, Pharmacokinetics, Breast cancer, Stomach, Conference, Spacecraft, Poster, Safety, MTD, Trial of the century, Pharmaceutical industry, Medical imaging, Trophoblast

The multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors aims to evaluate the safety and tolerability of BAT8008.

Key Points: 
  • The multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors aims to evaluate the safety and tolerability of BAT8008.
  • Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumors.
  • BAT8008 is an antibody-drug conjugate (ADC) targeting Trop2 designed for the treatment of solid tumors.
  • Bio-Thera Solutions is also developing additional ADCs based on its proprietary linker-payload, including ADCs targeting FRα, B7H3, Her2, Nectin-4.

MELANIE H. MUHLSTOCK OF PARKER WAICHMAN LLP NAMED TO LEADERSHIP ROLE IN NATIONAL HAIR RELAXER MARKETING SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION

Retrieved on: 
Monday, March 6, 2023
Ovarian cancer, Order, District court, Diagnosis, PSC, Endometrial cancer, Committee, Death, Injury, Woman, Uterine cancer, MDL, Bar, PORT, Superior court, Parker, Court, Plaintiff, Knowledge, Tobacco, Pentosan polysulfate

PORT WASHINGTON, N.Y., March 6, 2023 /PRNewswire/ -- Melanie H. Muhlstock, Managing Partner in the Mass Torts Department for the national law firm Parker Waichman LLP, has been named to the Plaintiffs' Steering Committee ("PSC") in the multi-district litigation (MDL) involving hair relaxer marketing sales practices and product liability litigation.

Key Points: 
  • PORT WASHINGTON, N.Y., March 6, 2023 /PRNewswire/ -- Melanie H. Muhlstock, Managing Partner in the Mass Torts Department for the national law firm Parker Waichman LLP, has been named to the Plaintiffs' Steering Committee ("PSC") in the multi-district litigation (MDL) involving hair relaxer marketing sales practices and product liability litigation.
  • Ms. Muhlstock brings to the group her substantial experience in mass torts litigation along with the extensive knowledge and experience of the Parker Waichman firm, long involved in multi-district litigation nationwide.
  • Ms. Muhlstock has often been selected to serve on discovery and expert sub-committees for Plaintiffs' Steering Committees nationwide.
  • 2973) and as Lead/Liaison Counsel in In Re: Tasigna Products Liability Litigation (Superior Court of New Jersey MCL No.

DiCello Levitt’s “Fu” Zimmermann Appointed to Lead Litigation Against L’Oréal and Others Over Cancer-Causing Hair Relaxer Products Marketed to Minority Women

Retrieved on: 
Friday, March 3, 2023
Legal, Women, Professional Services, Other Health, Health, Cosmetics, Consumer, Retail, Oncology, Lawyer, Woman, Formaldehyde, Metal, Douglas, National Cancer Institute, Kayla DiCello, Hearing, Risk, Paraben, National Institute for Health and Care Excellence, Douglas v. U.S. District Court ex rel Talk America, MDL, Abrasion, Uterine cancer, District court, Black

DiCello Levitt partner Diandra “Fu” Debrosse Zimmermann today was appointed Plaintiffs’ Co-Lead Counsel in a multidistrict litigation against L’Oréal and other makers of hair relaxer products marketed primarily to Black and Latin women, alleging that such products are directly linked to uterine and ovarian cancer.

Key Points: 
  • DiCello Levitt partner Diandra “Fu” Debrosse Zimmermann today was appointed Plaintiffs’ Co-Lead Counsel in a multidistrict litigation against L’Oréal and other makers of hair relaxer products marketed primarily to Black and Latin women, alleging that such products are directly linked to uterine and ovarian cancer.
  • Similar lawsuits followed before their transfer and centralization into the MDL, In Re: Hair Relaxer Marketing Sales Practices and Products Liability Litigation.
  • That finding was particularly alarming for Black women, who report using hair straightening products more than other populations.
  • Zimmermann and Crump founded the organization, Shades of Mass, in 2022 to combat the lack of diverse attorney leadership in MDLs.

Lieff Cabraser, Equal Justice Society, and Serna & Associates PLLC Announce Filing of Federal Injury Lawsuit in California Against L'Oreal, Softsheen, Dermoviva and Others for Cancer Allegedly Caused by Repeated Use of Hair Relaxer Products

Retrieved on: 
Tuesday, January 17, 2023
Legal, Professional Services, Dark, Olive, Disease, EWG, Cardiovascular disease, Toxicity, Hypertension, Environmental Working Group, Big Dark Love, Failure, Hunger, Pressure, Uterine cancer, Quality of life, Family, Safety, Just, Health, Social stigma, Fibroid, Marketing, Woman, Metastasis, Tubing (recreation), Diabetes, Cancer, Biophysical environment, Complaint, Bias, Bouquet (EP), Sale, Equal, Central District, Fraud, Advertising, Hair, L'Oréal, California Consumers Legal Remedies Act, Dabur, Distress, Insurance, Cosmetics, Birth control, Dietary supplement, Black, Plaintiff

In 2020, the global Black Hair care market was estimated at $2.5 billion, with the hair relaxer market alone estimated at $718 million in 2021.

Key Points: 
  • In 2020, the global Black Hair care market was estimated at $2.5 billion, with the hair relaxer market alone estimated at $718 million in 2021.
  • It is estimated that as many as 90% of Black women in the United States have used relaxer products.
  • This follows other studies which have raised concerns about the toxicity of ingredients in hair relaxers.
  • There was never any warning or labeling on the Products that normal use of the Products could cause her to develop cancer.

A Case for Women Stepping Up to Help Women in the Hair Relaxer Lawsuit

Retrieved on: 
Wednesday, December 21, 2022
Legal, Women, Other Retail, Professional Services, Other Health, General Health, Consumer, Health, Cosmetics, Retail, NBC News, News, Beauty, Multimedia, Marketing, NIH, Uterine cancer, Risk, Dietary supplement, Cosmetics, Black, Woman

A Case for Women LLC, a mission-driven organization focused on educating women about civil legal action, is increasing its efforts to inform women about dangerous styling products and the hair relaxer lawsuit .

Key Points: 
  • A Case for Women LLC, a mission-driven organization focused on educating women about civil legal action, is increasing its efforts to inform women about dangerous styling products and the hair relaxer lawsuit .
  • By partnering with national law firms known for taking on large defendants, A Case for Women hopes to make high quality, contingency-fee based legal assistance accessible to women who used hair relaxer products and have been diagnosed with uterine cancer.
  • Black women tend to be at higher risk for uterine cancer related to hair relaxer products due to the heavy use and early adoption of hair relaxer products in the community.
  • While there are dozens of hair relaxer products available, sample products include:

Koya Medical Announces the Addition of Chief Medical Officer Dr. Thomas Maldonado to Their Executive Leadership Team

Retrieved on: 
Tuesday, December 27, 2022
Dayspring, Breast cancer, Trauma, Venous insufficiency, Stasis dermatitis, Lymphedema, Education, Neoplasm, Koya, Food, Extremities, Head, Lymphoma, Stanford University School of Medicine, Leg, Uterine cancer, Melanoma, Academic health science centre, FDA, American Cancer Society, Ovarian cancer, Health, Multimedia, Publication, Wound healing, Pain, Vulvar cancer, Movement, Primary lymphedema, Arm, Edema, Vascular and Endovascular Surgery, Lipedema, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Maintenance, Prostate cancer, Pharmaceutical industry

OAKLAND, Calif., Dec. 27, 2022 /PRNewswire/ -- Koya Medical, a healthcare company on a mission to transform lymphatic and venous care through a comprehensive suite of innovative, people-centric platforms, today announced the addition of Dr. Thomas Maldonado as Chief Medical Officer. The addition of Dr. Maldonado further strengthens Koya Medical's clinical advisory board, led by Stanley Rockson, M.D., cardiologist and professor in the Falk Cardiovascular Research Center at Stanford University School of Medicine.

Key Points: 
  • OAKLAND, Calif., Dec. 27, 2022 /PRNewswire/ -- Koya Medical, a healthcare company on a mission to transform lymphatic and venous care through a comprehensive suite of innovative, people-centric platforms, today announced the addition of Dr. Thomas Maldonado as Chief Medical Officer.
  • The addition of Dr. Maldonado further strengthens Koya Medical's clinical advisory board, led by Stanley Rockson, M.D., cardiologist and professor in the Falk Cardiovascular Research Center at Stanford University School of Medicine.
  • has been one of New York City's top vascular surgeons in one of the nation's premier academic medical centers for over two decades.
  • He is regularly featured as Top Doctor by Castle Connolly and has served as president of numerous national and regional vascular societies.

Wallace Miller Files Suit Against L'Oreal Over Hair Relaxer Cancer Claims

Retrieved on: 
Wednesday, December 14, 2022
Diagnosis, Injury, Safety, Uterine cancer, L'Oréal, Insurance, Defendant

CHICAGO, Dec. 14, 2022 /PRNewswire-PRWeb/ -- Wallace Miller, the Chicago-based nationwide Plaintiffs law firm with extensive experience representing clients harmed by dangerous and defective products, announced the filing of a new lawsuit against L'Oreal and similarly situated Defendants over allegations that the company's hair relaxer products may increase the likelihood of developing uterine cancer and other health risks.

Key Points: 
  • Wallace Miller, the Chicago-based nationwide Plaintiffs law firm with extensive experience representing clients harmed by dangerous and defective products, announced the filing of a new lawsuit against L'Oreal and similarly situated Defendants over allegations that the company's hair relaxer products may increase the likelihood of developing uterine cancer and other health risks.
  • CHICAGO, Dec. 14, 2022 /PRNewswire-PRWeb/ -- Wallace Miller, the Chicago-based nationwide Plaintiffs law firm with extensive experience representing clients harmed by dangerous and defective products, announced the filing of a new lawsuit against L'Oreal and similarly situated Defendants over allegations that the company's hair relaxer products may increase the likelihood of developing uterine cancer and other health risks.
  • Plaintiff in this case is represented by Molly C. Wells and Edward A. Wallace of Wallace Miller.
  • More information is available at http://www.wallacemiller.com
    Wallace Miller is a is a nationally recognized plaintiffs' complex litigation law firm focusing on protecting people in virtually all aspects of their lives.

PARKER WAICHMAN LLP FILES LAWSUIT AGAINST L'OREAL, USA, INC. AND SOFT SHEEN-CARSON LLC IN HAIR RELAXER CLAIM

Retrieved on: 
Tuesday, December 13, 2022
District court, Injury, Uterine cancer, PORT, Cancer, Parker, LaDonna Harris, Complaint, Pain, Eastern Division, Woman, Quality of life, Multimedia, Fibroid, Safety, Hysterectomy, Endometrial cancer, Dietary supplement

Ms. Mahaffey, who began using hair relaxers at approximately age nine, both at home and in the salon.

Key Points: 
  • Ms. Mahaffey, who began using hair relaxers at approximately age nine, both at home and in the salon.
  • She often applied hair straightening products every two to three weeks.
  • Sadly, in June 2022, Ms. Mahaffey was diagnosed with endometrial cancer and underwent a complete hysterectomy, and then endured months of chemotherapy.
  • Ms. Mahaffey was shocked to learn in November 2022 that hair relaxers were the likely cause of her endometrial cancer.